See more : Anything Technologies Media, Inc. (EXMT) Income Statement Analysis – Financial Results
Complete financial analysis of Immatics N.V. (IMTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Immatics N.V., a leading company in the Biotechnology industry within the Healthcare sector.
- Koza Altin Isletmeleri A.S. (KOZAL.IS) Income Statement Analysis – Financial Results
- Equity Commonwealth (EQC-PD) Income Statement Analysis – Financial Results
- Toshiba Corporation (TOSYY) Income Statement Analysis – Financial Results
- Aries I Acquisition Corporation (RAM) Income Statement Analysis – Financial Results
- Atomos Limited (AMS.AX) Income Statement Analysis – Financial Results
Immatics N.V. (IMTX)
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 54.00M | 172.83M | 34.76M | 31.25M | 18.45M | 3.77M |
| Cost of Revenue | 118.66M | 106.78M | 87.57M | 67.08M | 40.09M | 33.97M |
| Gross Profit | -64.67M | 66.05M | -52.81M | -35.83M | -21.64M | -30.20M |
| Gross Profit Ratio | -119.76% | 38.22% | -151.92% | -114.65% | -117.31% | -801.09% |
| Research & Development | 118.66M | 106.78M | 87.57M | 67.09M | 40.09M | 33.97M |
| General & Administrative | 38.20M | 36.12M | 33.81M | 34.19M | 11.76M | 7.67M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.20M | 36.12M | 33.81M | 34.19M | 11.76M | 7.67M |
| Other Expenses | -1.14M | -26.00K | -332.00K | -303.00K | -385.00K | -3.46M |
| Operating Expenses | 155.72M | 142.88M | 121.05M | 100.97M | 51.46M | 38.18M |
| Cost & Expenses | 155.72M | 142.88M | 121.05M | 100.97M | 51.46M | 38.18M |
| Interest Income | 13.85M | 9.42M | 5.68M | 850.00K | 790.00K | 507.00K |
| Interest Expense | 831.00K | 8.28M | 1.73M | 289.00K | 170.00K | 16.00K |
| Depreciation & Amortization | 7.23M | 6.84M | 5.47M | 4.12M | 3.85M | 2.25M |
| EBITDA | -88.93M | 50.04M | -83.56M | -64.44M | -29.16M | -31.73M |
| EBITDA Ratio | -164.69% | 26.81% | -216.78% | -206.19% | -153.75% | -841.54% |
| Operating Income | -101.73M | 29.95M | -86.29M | -69.72M | -33.01M | -34.41M |
| Operating Income Ratio | -188.39% | 17.33% | -248.24% | -223.07% | -178.94% | -912.71% |
| Total Other Income/Expenses | 4.73M | 12.08M | -7.04M | -142.13M | 526.00K | 2.05M |
| Income Before Tax | -96.99M | 42.04M | -93.34M | -229.62M | -32.49M | -32.36M |
| Income Before Tax Ratio | -179.63% | 24.32% | -268.49% | -734.70% | -176.09% | -858.22% |
| Income Tax Expense | 0.00 | 4.55M | 1.73M | -268.00K | -746.00K | -2.97M |
| Net Income | -96.99M | 37.51M | -95.06M | -229.35M | -31.74M | -31.44M |
| Net Income Ratio | -179.63% | 21.71% | -273.45% | -733.84% | -172.05% | -834.06% |
| EPS | -1.20 | 0.55 | -1.51 | -4.78 | -0.50 | -0.50 |
| EPS Diluted | -1.20 | 0.54 | -1.51 | -4.78 | -0.50 | -0.50 |
| Weighted Avg Shares Out | 80.55M | 67.22M | 62.91M | 48.00M | 62.91M | 62.91M |
| Weighted Avg Shares Out (Dil) | 80.55M | 68.82M | 62.91M | 48.00M | 62.91M | 62.91M |
What Makes Immatics (IMTX) a New Buy Stock
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
Immatics: A Promising TCR Pipeline
Immatics Announces Pricing of $150 Million Public Offering
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
Immatics Announces Proposed $150 Million Public Offering
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Source: https://incomestatements.info
Category: Stock Reports